These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37610884)
1. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus. Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884 [TBL] [Abstract][Full Text] [Related]
2. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients. Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870 [TBL] [Abstract][Full Text] [Related]
3. Association of Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808 [TBL] [Abstract][Full Text] [Related]
4. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431 [TBL] [Abstract][Full Text] [Related]
5. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes. Liang H; Xu W; Zhou L; Yang W; Weng J Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905 [TBL] [Abstract][Full Text] [Related]
6. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345 [TBL] [Abstract][Full Text] [Related]
7. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes. Kim H; Bae S; Yoon HY; Yee J; Gwak HS J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991 [TBL] [Abstract][Full Text] [Related]
8. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study. Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983 [TBL] [Abstract][Full Text] [Related]
9. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146 [TBL] [Abstract][Full Text] [Related]
10. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus. Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994 [TBL] [Abstract][Full Text] [Related]
12. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Zolk O Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511 [TBL] [Abstract][Full Text] [Related]
13. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751 [TBL] [Abstract][Full Text] [Related]
14. Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes. Gonzalez-Covarrubias V; Sánchez-Ibarra H; Lozano-Gonzalez K; Villicaña S; Texis T; Rodríguez-Dorantes M; Cortés-Ramírez S; Lavalle-Gonzalez F; Soberón X; Barrera-Saldaña H Pharmacology; 2021; 106(11-12):588-596. PubMed ID: 34265779 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic variation and metformin response. Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113 [TBL] [Abstract][Full Text] [Related]
16. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099 [TBL] [Abstract][Full Text] [Related]
17. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778 [TBL] [Abstract][Full Text] [Related]
19. Population diversity of three variants of the SLC47A2 gene (MATE2-K transporter) in Mexican Mestizos and Native Americans. Favela-Mendoza AF; Fricke-Galindo I; Cuevas-Sánchez WF; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H Mol Biol Rep; 2021 Sep; 48(9):6343-6348. PubMed ID: 34383246 [TBL] [Abstract][Full Text] [Related]
20. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad. Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]